Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE

Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST<sub>2</sub>) peptide agonist [<sup>177</sup>Lu]Lu-DOTA-TATE is effective and well-established. Recent studies suggest improved therapeutic efficacy using the SST<sub>2</su...

Full description

Bibliographic Details
Main Authors: Rosalba Mansi, Pascale Plas, Georges Vauquelin, Melpomeni Fani
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Pharmaceuticals
Subjects:
somatostatin receptor
[<sup>177</sup>Lu]Lu-OPS201
[<sup>177</sup>Lu]Lu-DOTA-TATE
radioligand binding
kinetics
binding sites
Online Access:https://www.mdpi.com/1424-8247/14/12/1265

Internet

https://www.mdpi.com/1424-8247/14/12/1265

Similar Items